Portal de Periódicos da CAPES

The cytokine network in acute myeloid leukemia (AML): A focus on pro- and anti-inflammatory mediators

2018; Elsevier BV; Volume: 43; Linguagem: Inglês

10.1016/j.cytogfr.2018.08.004

1879-0305

Stephanie Binder, Michela Luciano, Jutta Horejs‐Hoeck,

Neutrophil, Myeloperoxidase and Oxidative Mechanisms

• Acute myeloid leukemia (AML) is a highly heterogeneous and aggressive type of blood cancer , and still the most common cause of leukemia-related mortality. • Cytokines exert profound effects on the progression of hematopoietic malignancies such as AML. • We believe that a beneficial approach to support AML therapy may be to target the dysregulated cytokine network in AML. • The proposed review provides an overview of the role of pro-and anti-inflammatory cytokines, their dysregulation, and their manifold functions in the context of AML. Cytokines exert profound effects on the progression of hematopoietic malignancies such as acute myeloid leukemia (AML). Critical roles of cytokines in the context of inflammation have gained special interest. While pro-inflammatory mediators such as IL-1β, TNF-α and IL-6 tend to increase AML aggressiveness, anti-inflammatory mediators such as TGF-β and IL-10 appear to impede AML progression. Dysregulation of the complex interactions between pro- and anti-inflammatory cytokines in AML may create a pro-tumorigenic microenvironment with effects on leukemic cell proliferation, survival and drug-resistance. This article summarizes current knowledge about the functions of pro- and anti-inflammatory cytokines in AML, their modes of action, and therapeutic interventions with potential to improve clinical outcomes for AML patients.